© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
September 21, 2022
In this interview, Howard Goldman, MD, discusses the development of sacral neuromodulation as a treatment for overactive bladder (OAB).
"[Sacral neuromodulation has] changed the treatment of OAB remarkably," says Howard B. Goldman, MD, FACS.
September 19, 2022
“We wanted to compare outcomes between nursing home residents and community-dwelling older adults undergoing surgery for bladder and bowel dysfunction,” explains Anne M. Suskind, MD.
August 30, 2022
“When it comes to encouraging patients to utilize this therapy the number 1 thing I say is that it is the most effective therapy out there on the market,” says Raveen Syan, MD.
August 17, 2022
“I think my goal in doing all this research is to draw awareness to these problems and the disparities,” says Elisabeth M. Sebesta, MD.
August 12, 2022
“Health care disparities are very complex issues; it’s not like a linear cause-and-effect relationship,” says Elisabeth M. Sebesta, MD.
August 11, 2022
“[We] found that women were spending on average, nearly $35 a week on incontinence products in the highest symptom severity, which is a huge financial burden,” says Elisabeth M. Sebesta, MD.
August 10, 2022
“I’ve been using it my practice and also based on the literature, it seems like it is a relatively safe extract with little to no change in sexual function…and no obvious contraindications,” says Bilal Chughtai, MD.
Sacral neuromodulation administered through an implantable neurostimulator has shown promise as a therapy for patients with bladder and bowel dysfunction.
August 08, 2022
Axonics F15, a recharge-free sacral neuromodulation implantable neurostimulator for the treatment of patients with bladder and bowel dysfunction, was approved by the FDA earlier this year.